Huntington’s disease Clinical Trials Corner: February 2018 by Rodrigues, Filipe Brogueira & Wild, Edward J.




Huntington’s Disease Clinical Trials
Corner: February 2018
Filipe B. Rodriguesa,b,c and Edward J. Wilda,∗
aHuntington’s Disease Centre, University College London, UK
bLaboratory of Clinical Pharmacology and Therapeutics, Faculty of Medicine, University of Lisbon, Portugal
cClinical Pharmacology Unit, Instituto de Medicina Molecular, Lisbon, Portugal
Abstract. In the second edition of the Huntington’s Disease Clinical Trials Corner we list all currently registered and ongoing
clinical trials, summarise the top-line results of the recently-announced IONIS-HTTRX trial (NCT02519036), expand on Wave
Life Sciences’ PRECISION-HD1 (NCT03225833) and PRECISION-HD2 (NCT03225846), and cover one recently finished
trial: the FIRST-HD deutetrabenazine trial (NCT01795859).
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INTRODUCTION
The Huntington’s Disease Clinical Trials Corner
is a regular section devoted to highlighting ongoing
and recently completed clinical trials in Huntington’s
disease (HD). Clinical trials previously reviewed by
the Huntington’s Disease Clinical Trials Corner are
listed in Table 1.
Table 1
Clinical trials previously reviewed by the Huntington’s Disease
Clinical Trials Corner
Registration ID Trial name Intervention Edition
NCT02519036 IONIS-HTTRx IONIS-HTTRx September
NCT02215616 LEGATO-HD Laquinimod 2017(6)
NCT02197130 Amaryllis PF-02545920
NCT02006472 Pride-HD Pridopidine
In this edition, we summarise the recently-
announced top-line results from the phase 1b/2a
IONIS-HTTRX huntingtin-lowering antisense
oligonucleotide (ASO) trial (NCT02519036) [1];
highlight the new Wave Life Sciences allele-selective
∗Correspondence to: Edward J. Wild, UCL Huntington’s Dis-
ease Centre, Russell Square 10-12, London, WC1B 5EH, UK.
E-mail: e.wild@ucl.ac.uk.
ASO trials, PRECISION-HD1 (NCT03225833) [2]
and PRECISION-HD2 (NCT03225846) [3],
and summarise the results of the FIRST-HD
(NCT01795859) [4, 5] trial of deutetrabenazine.
Finally we tabulate all currently registered and
ongoing clinical trials in Tables 2 to 4. For fur-
ther details on the methodology used please refer to
the September 2017 edition of Huntington’s Disease
Clinical Trials Corner [6].
If you would like to draw attention to specific
trials, please feel free to email us at: E-mails:
f.rodrigues@ucl.ac.uk and e.wild@ucl.ac.uk.
BREAKING NEWS
December 11th 2017 saw the initial announce-
ment of top-line results from the first-in-human phase
1b/2a trial of IONIS-HTTRX, the first ASO designed
to lower huntingtin protein (HTT) to be tested in peo-
ple with HD (NCT02519036) [1]. The announcement
came in the form of a press release from the sponsor,
Ionis Pharmaceuticals [7], and was followed by sub-
stantial media coverage [8, 9]. As we detailed in the
previous Clinical Trials Corner [6], the trial had safety
as its primary endpoint. Encouragingly, the release
reported that “the safety and tolerability profile . . .
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supports continued development”. More excitingly,
dose-dependent reductions in cerebrospinal fluid
mutant huntingtin concentration were seen in patients
who received IONIS-HTTRx. C. Frank Bennett,
Ionis’ Senior Vice President of Research, noted
that the mutant huntingtin reduction “substantially
exceeded our expectations”. As a result, Roche has
exercised its option to license the drug and will now
be responsible for future development of the program.
In a separate statement for the HD community, Ionis
confirmed that an efficacy trial was planned and that
“future studies for the program will be conducted
globally, including in the US” [10]. Meanwhile, an
open-label extension is underway for the 46 partic-
ipants who took part in the original study (Table 2,
NCT03342053) [11].
This is a significant positive announcement in
a therapeutic program with substantial promise for
disease-modification in HD. Naturally, it will need to
be supported by release of more detailed data from the
trial, and peer-reviewed publication of the results. The
sponsor has committed to supplying these updates in
the first half of 2018 [10].
ONGOING CLINICAL TRIALS
A list of all ongoing clinical trials is given in
Tables 2, 3 and 4.
PRECISION-HD1 (NCT03225833) and
PRECISION-HD2 (NCT03225846)
Study titles: A Multicenter, Randomized, Double-
blind, Placebo-controlled, Phase 1b/2a Study of
WVE-120101 Administered Intrathecally in Patients
With Huntington’s Disease [2] and A Multicen-
ter, Randomized, Double-blind, Placebo-controlled,
Phase 1b/2a Study of WVE-120102 Adminis-
tered Intrathecally in Patients With Huntington’s
Disease [3].
Intervention: Respectively WVE-120101 and
WVE-120102, two distinct allele-selective ASOs
[12].
Description: The PRECISION-HD trials aim to
compare the safety, tolerability, pharmacokinet-
ics and pharmacodynamics of single and multiple
ascending doses of WVE-120101 and WVE-120102,
respectively, administered intrathecally, comparing
with intrathecal placebo, for disease modification
in people with HD (i.e. clinical diagnostic motor
features of HD, a Unified Huntington’s Disease Rat-
ing Scale (UHDRS) Diagnostic Confidence Level of
4, and a UHDRS Total Functional Capacity (TFC)
between 13 and 7, inclusively) who carry a targeted
single nucleotide polymorphism (SNP) rs362307 or
rs362331, respectively, and are aged between 25 and
65 years old.
These trials are phase 1b/2a, multi-centre, interna-
tional, randomized, placebo controlled, double-blind,
parallel studies. They have a combined single ascend-
ing dose/multiple ascending dose design, comprising
four cohorts of progressively higher ASO doses. In
each cohort, participants will be allocated to receive
a single dosage or three dosages of the ASO or a
placebo. Each trial has the recruitment target of 48
participants; currently recruitment is open in Canada
and Poland. The WVE-120101 and WVE-120102
compounds are ASOs targeting the pre-mRNA tran-
script of two allelic variants linked to the expanded
CAG repeat tract in the HTT gene, with the aim of
selectively reducing the production of mutant hunt-
ingtin protein while leaving the level of wild-type
huntingtin protein relatively unaltered. Each partici-
pant’s involvement will last for 210 days.
The primary outcome is safety and tolerabil-
ity at 210 days. The secondary outcomes involve
pharmacokinetic measurements in plasma; pharma-
codynamic measures in cerebrospinal fluid, including
mutant huntingtin; and the UHDRS TFC.
Sponsors/funders: Wave Life Sciences Ltd.
Comments: The CAG expansion in the HTT gene
is frequently allelically linked to three different SNPs
that collectively are thought to be present in at least
80% of the gene expansion carriers of European
ancestry [13]. These two trials are running in par-
allel and will target two of these SNPs. Participants’
DNA samples will first be screened for the presence
of one of both SNPs, and then further tested to estab-
lish whether either SNP is allelic to the HTT CAG
expansion.
While the molecule tested in the IONIS-HTTRx
trial and its open-label extension (NCT02519036) [1]
is expected to reduce the translation of both wild-type
and mutant pre-mRNA, the PRECISION-HD ASOs
were designed to target selectively the mutant pre-
mRNA and mark it for degradation by RNase H. This
selectivity is attained by means of targeting the most
frequent SNPs associated with mutant HTT. The the-
oretical advantage is that this may reduce the potential
long-term risk stemming from lowering of wild-type
huntingtin and associated loss-of-function [14].
However, it is also worth noting that no safety
concerns have so far been identified in the ongoing,
allele-nonselective IONIS-HTTRx programme [6].
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Wave’s platform is also distinguished by the abil-
ity to specify the chirality of each phosphorothioate
bond in the ASO backbone, which has the potential
to improve characteristics such as stability and tar-
get mRNA degradation [15]. Each approach – both
in terms of chiral purity and allele-selectivity – has
potential advantages and disadvantages [12]. Each
SNP-selective compound will have to go through
independent testing and approval; the testing process
to establish suitability is novel and time-consuming;
and some mutation-carriers will be ineligible by
virtue of possessing no suitable SNPs.
Together, the Wave and IONIS platforms will be
informative and provide safety and efficacy informa-
tion relating to different HTT lowering approaches.
COMPLETED CLINICAL TRIALS
FIRST-HD (NCT01795859)
Study title: A Randomized Double-Blind, Placebo-
Controlled Study of SD-809 Extended Release for
the Treatment of Chorea Associated With Huntington
Disease [4, 16].
Intervention: Deutetrabenazine or SD-809, a
vesicular monoamine transporter type 2 (VMAT2)
selective inhibitor.
Description: The goal of FIRST-HD trial was to
compare the efficacy and safety of oral deutetra-
benazine against an oral placebo, both taken twice
daily and titrated to optimal dosage, for symptomatic
relief of chorea in adults with stage 1 to 3 manifest
HD (i.e. motor signs characteristic of HD plus HTT
CAG repeat length ≥36 plus a UHDRS TFC ≥ 5) and
with significant chorea (i.e. a UHDRS total maximum
chorea score (TMC) of 8 or higher).
This trial was a phase 3, multi-centre, international,
randomized, placebo controlled, double blind, paral-
lel study. It recruited 90 participants from Canada and
the United States. Participant involvement lasted for
13 weeks.
The primary outcome was change from base-
line in the UHDRS TMC at weeks 9 and 12. The
UHDRS TMC is a subscore of UHDRS total motor
score (TMS) that only includes the chorea-related
items, and ranges from 0 to 28. The secondary out-
comes were the Patient Global Impression of Change
(PGIC), the Clinician Global Impression Change
(CGIC), the Short Form 36 Health Survey (SF-36),
the Berg Balance Test (BBT), and adverse events.
Sponsors/funders: Teva Pharmaceutical Industries
Results: The trial was completed on December
2014 and the results published in July 2016 [16]. It
showed deutetrabenazine to be superior to placebo
in decreasing chorea associated with HD, objec-
tively and subjectively, and to improve quality of
life, but not balance. Interestingly, in a post-hoc
analysis, dystonia subscores on TMS also lessened
with deutetrabenazine. In regards to safety, deutetra-
benazine was comparable with placebo, with the
exception of weight gain that was more prevalent in
the active treatment arm. It is noteworthy that this
study was not powered to investigate adverse events
and further information is required to draw definitive
conclusions about safety.
In April 2017, the FDA approved this drug for
the treatment of chorea associated with HD. Like
tetrabenazine, its label includes a contraindication for
patients who are suicidal, or who have untreated or
inadequately treated depression.
Deutetrabenazine is a modified version of tetra-
benazine containing deuterium (i.e. a stable isotope
of hydrogen with mass number of 2) in strategic posi-
tions. This modification is intended to provide better
pharmacokinetic properties (i.e. slower enzymatic
degradation) to this otherwise chemically-identical
compound, due to stronger bonds between carbon and
deuterium.
Still, little is known about how deutetrabenazine
compares with tetrabenazine, an older VMAT2
inhibitor also approved by FDA. In ARC-HD–a mul-
ticentre, international, single arm, open label study
– the Huntington Study Group explored the safety
of switching overnight from a stable and effica-
cious dosage of tetrabenazine to deutetrabenazine
(NCT01897896) [17]. In a preliminary report, about
50% of the sample had at least one adverse event,
but the drug was well tolerated with low rates of
neuropsychiatric adverse events [18].
Unfortunately no head-to-head blinded compari-
son has been made between these compounds or is
planned. Indirect treatment comparisons showed no
apparent efficacy difference [19]. The safety results
are contradictory [19, 20], possibly due to a statistical
artefact [21]. Overall these results call for close post-
licensing surveillance to guide informed prescribing
decisions.
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